ECSP22046050A - Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr - Google Patents
Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftrInfo
- Publication number
- ECSP22046050A ECSP22046050A ECSENADI202246050A ECDI202246050A ECSP22046050A EC SP22046050 A ECSP22046050 A EC SP22046050A EC SENADI202246050 A ECSENADI202246050 A EC SENADI202246050A EC DI202246050 A ECDI202246050 A EC DI202246050A EC SP22046050 A ECSP22046050 A EC SP22046050A
- Authority
- EC
- Ecuador
- Prior art keywords
- conditions mediated
- heterolaminosulfonamides
- cftr activity
- treat conditions
- deficient cftr
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 230000002950 deficient Effects 0.000 title 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invenci?n est? relacionada con compuestos de heteroarilo, sales farmac?uticamente aceptables de estos, y preparaciones farmac?uticas de estos. En la presente tambi?n se describen composiciones y el uso de esos compuestos en m?todos de tratamiento de enfermedades y afecciones mediadas por la deficiencia de la actividad del CFTR, en particular la fibrosis qu?stica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962934293P | 2019-11-12 | 2019-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP22046050A true ECSP22046050A (es) | 2022-08-31 |
Family
ID=73740547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202246050A ECSP22046050A (es) | 2019-11-12 | 2022-06-09 | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr |
Country Status (16)
Country | Link |
---|---|
US (1) | US20240002374A1 (es) |
EP (1) | EP4058439A1 (es) |
JP (1) | JP2023500408A (es) |
KR (1) | KR20220115829A (es) |
CN (1) | CN115003659A (es) |
AU (1) | AU2020384279A1 (es) |
BR (1) | BR112022009185A2 (es) |
CA (1) | CA3158057A1 (es) |
CL (1) | CL2022001245A1 (es) |
CO (1) | CO2022007953A2 (es) |
EC (1) | ECSP22046050A (es) |
IL (1) | IL292966A (es) |
JO (1) | JOP20220105A1 (es) |
MX (1) | MX2022005809A (es) |
PE (1) | PE20221461A1 (es) |
WO (1) | WO2021097057A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3752510T (lt) | 2018-02-15 | 2023-04-11 | Vertex Pharmaceuticals Incorporated | Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
JP2022544383A (ja) | 2019-08-14 | 2022-10-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrモジュレータの結晶形態 |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
US20230373939A1 (en) * | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CN113480416B (zh) * | 2021-07-12 | 2023-03-21 | 重庆大学 | 一种芳基酮的制备方法 |
CN114835655A (zh) * | 2022-04-14 | 2022-08-02 | 河南师范大学 | 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法 |
WO2024097227A1 (en) | 2022-10-31 | 2024-05-10 | Sionna Therapeutics | Methods of treating cftr-mediated diseases or disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69132293D1 (de) * | 1991-03-07 | 2000-08-10 | Hisamitsu Pharmaceutical Co | Diphenylthiazolderivate mit antiinflammatorischer aktivität |
DE69526958T2 (de) * | 1994-11-29 | 2003-01-16 | Hisamitsu Pharmaceutical Co | Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten |
EP1441732A2 (en) * | 2001-11-08 | 2004-08-04 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivative and pharmaceutical use thereof |
WO2016183173A1 (en) * | 2015-05-12 | 2016-11-17 | Avista Pharma Solutions | Antiparasitic compounds |
US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
TW201811766A (zh) * | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
-
2020
- 2020-11-12 IL IL292966A patent/IL292966A/en unknown
- 2020-11-12 MX MX2022005809A patent/MX2022005809A/es unknown
- 2020-11-12 EP EP20820656.5A patent/EP4058439A1/en active Pending
- 2020-11-12 KR KR1020227019502A patent/KR20220115829A/ko unknown
- 2020-11-12 JP JP2022527081A patent/JP2023500408A/ja active Pending
- 2020-11-12 BR BR112022009185A patent/BR112022009185A2/pt unknown
- 2020-11-12 JO JOP/2022/0105A patent/JOP20220105A1/ar unknown
- 2020-11-12 AU AU2020384279A patent/AU2020384279A1/en active Pending
- 2020-11-12 PE PE2022000772A patent/PE20221461A1/es unknown
- 2020-11-12 CN CN202080092755.2A patent/CN115003659A/zh active Pending
- 2020-11-12 CA CA3158057A patent/CA3158057A1/en active Pending
- 2020-11-12 WO PCT/US2020/060180 patent/WO2021097057A1/en active Application Filing
-
2022
- 2022-05-11 US US17/742,169 patent/US20240002374A1/en active Pending
- 2022-05-12 CL CL2022001245A patent/CL2022001245A1/es unknown
- 2022-06-03 CO CONC2022/0007953A patent/CO2022007953A2/es unknown
- 2022-06-09 EC ECSENADI202246050A patent/ECSP22046050A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2022001245A1 (es) | 2023-03-10 |
AU2020384279A1 (en) | 2022-05-26 |
MX2022005809A (es) | 2022-06-08 |
BR112022009185A2 (pt) | 2022-07-26 |
JP2023500408A (ja) | 2023-01-05 |
PE20221461A1 (es) | 2022-09-21 |
EP4058439A1 (en) | 2022-09-21 |
WO2021097057A1 (en) | 2021-05-20 |
IL292966A (en) | 2022-07-01 |
JOP20220105A1 (ar) | 2023-01-30 |
KR20220115829A (ko) | 2022-08-18 |
CA3158057A1 (en) | 2021-05-20 |
CO2022007953A2 (es) | 2022-09-09 |
CN115003659A (zh) | 2022-09-02 |
US20240002374A1 (en) | 2024-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22046050A (es) | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr | |
CO2022007946A2 (es) | Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de cftr deficiente | |
CO2020001743A2 (es) | Métodos de tratamiento para la fibrosis quística | |
AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
MX2019012676A (es) | Derivados de 2-aminoquinolina. | |
WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
MX2021004431A (es) | Procesos novedosos. | |
MX2019007587A (es) | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. | |
MD3442972T2 (ro) | Inhibitori ai bromodomeniului | |
EP4306523A3 (en) | Imidazoquinoline compounds and uses thereof | |
NO20013859D0 (no) | Cyklooksygenase-2 inhibitorpreparater som raskt gir terapeutisk effekt | |
CY1121326T1 (el) | Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες | |
EA202192905A1 (ru) | Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли | |
CL2022000458A1 (es) | Ciertos compuestos de pladienolida y métodos de uso. (divisional de solicitud 202002604) | |
WO2017091767A3 (en) | Drug formulations for cancer treatment | |
WO2020231739A3 (en) | Compounds and methods for treating cancer | |
MX2019004375A (es) | Inhibidores de bromodominios. | |
MX2019004187A (es) | Inhibidores de bromodominios. | |
MX2017012188A (es) | Inhibidores de beta-secretasa 1 (bace1). | |
EA201991817A1 (ru) | Интраназальная композиция, включающая бетагистин | |
CO2021002980A2 (es) | Formulaciones de dendrímeros | |
EA202191378A1 (ru) | Активные сложноэфирные производные тестостерона, их композиции и применения | |
CL2020001791A1 (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. | |
EA202190766A1 (ru) | Иммуномодуляторы, их композиции и способы применения | |
AR108792A1 (es) | Composiciones que comprenden timolol |